. 2011 Mar 15;203(6):780–790. doi: 10.1093/infdis/jiq118

Table 4.

No Significantly Increased Risk of CVD-Associated Events in HIV-Infected Subjects Conferred by Levels of Markers of Enterocyte Damage, Microbial Translocation, or the Immune Response to Microbial Translocation at Baseline

		25^th–49^th Percentile		50^th–74^th Percentile		>75^th Percentile
Biomarker	<25^th Percentile (Ref)	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
sCD14 level, ×10⁶ pg/mL
N (case patients/control subjects)	25/65	28/61		31/58		36/54
Univariate OR	1.0	1.1 (0.6–2.1)	.66	1.4 (0.7–2.6)	.32	1.7 (0.9–3.2)	.09
LPS level, pg/mL
N (case patients/control subjects)	33/56	30/60		26/64		31/58
Univariate OR	1.0	0.9 (0.5–1.6)	.62	0.7 (0.4– 1.3)	.26	0.9 (0.5–1.7)	.79
I-FABP level, pg/mL
N (case patients/control subjects)	39/91	20/28		28/61		33/56
Univariate OR	1.0	1.6 (0.8–3.3)	.15	1.1 (0.6–1.9)	.81	1.3 (0.8–2.4)	.31
16S rDNA level, copies/μL
N (case patients/control subjects)	34/55	28/62		27/62		31/59
Univariate OR	1.0	0.7 (0.4–1.3)	.24	0.6 (0.3–1.2)	.16	0.8 (0.4–1.5)	.51
EndoCAb level, MMU/mL
N (case patients/control subjects)	32/57	34/56		31/58		23/67
Univariate OR	1.0	1.1 (0.6–2.0)	.73	1.0 (0.5–1.8)	.90	0.6 (0.3–1.2)	.13

NOTE. Percentile cutoff points are LPS: <25.0, 25.0–33.5, 33.5–45.0, >45.0; soluble CD14: <2.02, 2.02–2.35, 2.36–2.71, >2.71; I-FABP: <.91, .91–142.19, 142.20–414.59, >414.59; 16S ribosomal DNA: <3.4, 3.4–7.8, 7.9–13.9, >13.9; EndoCAb: <43.0, 43.0–115.0, 116.0–169.0, >169.0. CI, confidence interval; CVD, cardiovascular disease; EndoCAb, endotoxin core antibody; HIV, human immunodeficiency virus; I-FABP, intestinal fatty acid binding protein; LPS, lipopolysaccharide; OR, odds ratio; rDNA, ribosomal DNA; Ref, reference; sCD14, soluble CD14.